Lee.kathryn S

Biography

    KATHERINE LEE is currently a Pharmaceutical Sciences Team Leader (PSTL) in the Portfolio and Project Management group within Pfizer’s Biotherapeutics Pharmaceutical Sciences. He is currently leading a team of talented colleagues in the development of Pfizer’s Chimeric Antigen Receptor T cell (CART) programs. This includes defining the GMP manufacturing strategy and CMC package for various health authorities. Previously, he has worked on several of Pfizer’s pre-POC programs. He has worked in both technical assay development (Bioassay) and project leadership roles (Analytical lead and PSTL) over the last 9 years. In addition, he has served on various Expert Working Groups, including the Immunogenicity and Biologics Control Strategy EWGs. Bruce received his B.A. in Biology cum laude from the University of Louisville, followed by a M.S. in Biochemistry at The Ohio State University and a Ph.D. in Microbiology and Immunology at the University of Louisville School of Medicine. Following postdoctoral work at Washington University in St. Louis in the labs of Drs. David Fremont and Michael Diamond, he joined Pfizer in 2008.     KATHERINE LEE is currently a Pharmaceutical Sciences Team Leader (PSTL) in the Portfolio and Project Management group within Pfizer’s Biotherapeutics Pharmaceutical Sciences. He is currently leading a team of talented colleagues in the development of Pfizer’s Chimeric Antigen Receptor T cell (CART) programs. This includes defining the GMP manufacturing strategy and CMC package for various health authorities. Previously, he has worked on several of Pfizer’s pre-POC programs. He has worked in both technical assay development (Bioassay) and project leadership roles (Analytical lead and PSTL) over the last 9 years. In addition, he has served on various Expert Working Groups, including the Immunogenicity and Biologics Control Strategy EWGs. Bruce received his B.A. in Biology cum laude from the University of Louisville, followed by a M.S. in Biochemistry at The Ohio State University and a Ph.D. in Microbiology and Immunology at the University of Louisville School of Medicine. Following postdoctoral work at Washington University in St. Louis in the labs of Drs. David Fremont and Michael Diamond, he joined Pfizer in 2008.

Research Interest

 Biotherapeutics Pharmaceutical Sciences